A phthalimidoalkanamide derived novel DNMT inhibitor enhanced radiosensitivity of A549 cells by inhibition of homologous recombination of DNA damage.

Investigational New Drugs
Hyun-Cheol KangEunsook Ma

Abstract

Purpose To elucidate the radiosensitizing effect and underlying mechanism of a new kind of DNA methyltransferase (DNMT) inhibitor with biological availability. Methods A novel non-nucleoside compound, designated as MA-17, was recently derived from a phthalimido alkanamide structure. DNMT expressions were confirmed in cultured human lung cancer (A549) and normal astrocyte (NHA) cells, radiosensitivity was measured using clonogenic assay, and assays of cell cycle alteration, apoptosis, DNA damage repair, and differential gene expression were undertaken. Results MA-17 significantly radiosensitized A549 cells with a mean dose enhancement ratio (DER) of 1.43 at the surviving fraction of 0.2 (p < 0.05 by one-tailed ratio paired t-test). MA-17 did not affect normal astrocytes (mean DER0.2, 1.016; p = 0.420). MA-17 demonstrated a mean half-life of 1.0 h in vivo and a relatively even distribution in various tissues. Pretreatment with MA-17 increased sub-G1 fractions and inhibited the repair of DNA double-strand breaks, which are induced by irradiation. We found that MA-17 also down-regulated DNA homologous recombination and the Fanconi anemia pathway (FANCA, BRCA1, and RAD51C) in A549 cells. This bioinformatics finding was confirmed in ...Continue Reading

References

Dec 11, 1999·Nucleic Acids Research·M Kanehisa, S Goto
Jan 5, 2002·Acta Oncologica·R A Gatti
Jun 17, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hideaki DotePhilip J Tofilon
Jul 5, 2005·The Lancet Oncology·Kevin M PriseKathryn D Held
Jan 3, 2007·Nature Cell Biology·Bryan M Turner
Feb 27, 2007·Cell·Peter A Jones, Stephen B Baylin
Aug 3, 2007·Nature·Stephen B Baylin, Kornel E Schuebel
May 17, 2008·Molecular Cancer Therapeutics·José A CasadoJuan A Bueren
Feb 14, 2009·International Journal of Radiation Oncology, Biology, Physics·Harlinde De SchutterSandra Nuyts
May 26, 2009·Nucleic Acids Research·Jing ChenAnil G Jegga
Mar 10, 2011·Nature Medicine·Manuel Rodríguez-Paredes, Manel Esteller
Dec 7, 2011·Drugs·Sang-Hyun SongYung-Jue Bang
Mar 20, 2012·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Chara PapadakiJohn Souglakos
Aug 25, 2012·Cancer Biotherapy & Radiopharmaceuticals·Li WangJuLun Yang
Oct 20, 2012·International Journal of Radiation Oncology, Biology, Physics·Sun Hyun BaeSang Bum Kim
Nov 10, 2012·Archives of Pharmacal Research·Hak Jae KimBeom Soo Shin
Apr 12, 2013·Frontiers in Genetics·Matt Merrifield, Olga Kovalchuk
May 28, 2014·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·Kim M SmitsPhilippe Lambin
Oct 18, 2015·Nucleic Acids Research·Minoru KanehisaMao Tanabe
Dec 23, 2015·Clinical Epigenetics·Clara NerviGiovanni Codacci-Pisanelli
Dec 3, 2016·Nucleic Acids Research·Minoru KanehisaKanae Morishima

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Astrocytes in Repair & Regeneration

Astrocytes are glial cells found within the CNS and are able to regenerate new neurons. They become activated during CNS injury and disease. The activation leads to the transcription of new genes and the repair and regeneration of neurons. Discover the latest research on astrocytes in repair and regeneration here.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.